Vieillard-Baron, Antoine
Naeije, R.
Haddad, F.
Bogaard, H. J.
Bull, T. M.
Fletcher, N.
Lahm, T.
Magder, S.
Orde, S.
Schmidt, G.
Pinsky, M. R.
Article History
Received: 19 February 2018
Accepted: 7 April 2018
First Online: 9 May 2018
Compliance with ethical standards
:
: AVB has received Grant from GSK for conducting clinical research and is membership of the scientific advisory board. RN has relationship with drug companies including AOPOrphan Pharmaceuticals, Actelion, Reata, Lung Biotechnology Corporation and United Therapeutics. In addition to being investigator in trials involving these companies, relationships include consultancy service, research Grants, and membership of scientific advisory board. FH declares no conflict of interest with regards to the content of this manuscript. HJB declares research Grants from Actelion, GSK, Therabell and speaker fees from Actelion, GSK. TMB declares investigator initiated Grant from Bayer Pharmaceuticals NF declares no conflict of interest. TL declares conflict of interest with Bayer (speaker bureau), Actelion (consulting), Gilled (scientific review committee) and Eli Lilly (research reagents). SM declares no conflict of interest with regards to the content of this manuscript. SO declares no conflict of interest. GS declares no conflict of interest with regards to the content of this manuscript. MRP declares no conflict of interest with regards to the content of this manuscript.